A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge
about
Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknownThe challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccineTransferrin conjugation confers mucosal molecular targeting to a model HIV-1 trimeric gp140 vaccine antigen.Induction of interferon-λ contributes to TLR3 and RIG-I activation-mediated inhibition of herpes simplex virus type 2 replication in human cervical epithelial cells.Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs.Linear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunityAdvances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonistsNasolacrimal duct closure modulates ocular mucosal and systemic CD4(+) T-cell responses induced following topical ocular or intranasal immunization.Asymptomatic HLA-A*02:01-restricted epitopes from herpes simplex virus glycoprotein B preferentially recall polyfunctional CD8+ T cells from seropositive asymptomatic individuals and protect HLA transgenic mice against ocular herpes.Stepwise release of biologically active HMGB1 during HSV-2 infection.Associations of HLA-A, HLA-B and HLA-C alleles frequency with prevalence of herpes simplex virus infections and diseases across global populations: implication for the development of an universal CD8+ T-cell epitope-based vaccine.Prophylactic and therapeutic modulation of innate and adaptive immunity against mucosal infection of herpes simplex virusTopical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challengeDevelopment of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in miceHLA-A02:01-restricted epitopes identified from the herpes simplex virus tegument protein VP11/12 preferentially recall polyfunctional effector memory CD8+ T cells from seropositive asymptomatic individuals and protect humanized HLA-A*02:01 transgeniOf mice and not humans: how reliable are animal models for evaluation of herpes CD8(+)-T cell-epitopes-based immunotherapeutic vaccine candidates?Phenotypic and functional characterization of herpes simplex virus glycoprotein B epitope-specific effector and memory CD8+ T cells from symptomatic and asymptomatic individuals with ocular herpesTherapeutic immunization with a mixture of herpes simplex virus 1 glycoprotein D-derived “asymptomatic” human CD8+ T-cell epitopes decreases spontaneous ocular shedding in latently infected HLA transgenic rabbits: association with low frequency of lA Herpes Simplex Virus Type 1 Human Asymptomatic CD8+ T-Cell Epitopes-Based Vaccine Protects Against Ocular Herpes in a "Humanized" HLA Transgenic Rabbit Model.Developing an asymptomatic mucosal herpes vaccine: the present and the future.The herpes simplex virus type 1 latency-associated transcript inhibits phenotypic and functional maturation of dendritic cells.Future of an "Asymptomatic" T-cell Epitope-Based Therapeutic Herpes Simplex VaccineComparison of the host immune response to herpes simplex virus 1 (HSV-1) and HSV-2 at two different mucosal sites.Targeting the genital tract mucosa with a lipopeptide/recombinant adenovirus prime/boost vaccine induces potent and long-lasting CD8+ T cell immunity against herpes: importance of MyD88.Strategies for intranasal delivery of vaccinesMucosal herpes immunity and immunopathology to ocular and genital herpes simplex virus infections.Current trends in negative immuno-synergy between two sexually transmitted infectious viruses: HIV-1 and HSV-1/2.The Herpes Simplex Virus Latency-Associated Transcript Gene Is Associated with a Broader Repertoire of Virus-Specific Exhausted CD8+ T Cells Retained within the Trigeminal Ganglia of Latently Infected HLA Transgenic RabbitsProtective effects of red ginseng extract against vaginal herpes simplex virus infection.Asymptomatic memory CD8+ T cells: from development and regulation to consideration for human vaccines and immunotherapeuticsNovel approaches in fighting herpes simplex virus infectionsNew concepts in herpes simplex virus vaccine development: notes from the battlefield.FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection.TLR7/8 agonist induces a post-entry SAMHD1-independent block to HIV-1 infection of monocytes.Human Asymptomatic Epitopes Identified from the Herpes Simplex Virus Tegument Protein VP13/14 (UL47) Preferentially Recall Polyfunctional Effector Memory CD44high CD62Llow CD8+ TEM Cells and Protect Humanized HLA-A*02:01 Transgenic Mice against OculHSV-2 vaccine: current status and insight into factors for developing an efficient vaccine.CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization.Toll-like receptors and genital tract infection.Genital Chlamydia trachomatis: understanding the roles of innate and adaptive immunity in vaccine research.The ongoing pursuit of a prophylactic HSV vaccine.
P2860
Q21296712-73B8DC7C-7BAA-46F9-834F-196221F083A6Q27021292-733D280D-F313-4F42-A12C-B32597727298Q30468622-B8BD33ED-7B49-4327-B947-AB40945DDF7DQ30683907-0F2F86C7-6916-48A9-9FC9-9096BC6F11CDQ33595097-EF7A8810-EA71-4A11-8908-8729F3040244Q33614657-E78F1FC4-0684-44A0-A311-7669A8C7DD9EQ33721641-F4C695C3-FF09-4F7E-9B78-63EB340870FFQ33725145-FE4B52B7-5B62-4435-A44C-B18BD6AC27CEQ33755236-C697A47F-1CA3-4A69-BDD9-E3C642D03607Q33809521-54312D4B-8C22-4242-A99E-E3E275DE16C3Q33993731-08FD1809-8279-4162-9C33-0A477E6A4E17Q34105712-2CA6EA8E-115C-4990-9219-36C0244CFDD1Q34992660-FC5A9691-C67A-4232-B09C-B27741454A08Q35076638-25693290-3F2D-4C1C-9782-98F3EC9FB61DQ35122383-23108A51-17C4-4537-8529-501B857599E2Q35173777-BD7F84A4-4758-444B-907B-9A26FDD814E0Q35487893-0D2BA250-FFBC-48A7-819F-BC016025E927Q35745358-855F4CE2-C144-4F66-927A-EFDA193241FDQ35769258-02F241F5-D94B-4E67-8825-4A49E9DB09DAQ35881975-914CE9FF-1082-4D9E-AA9C-283B204FAB00Q36005107-7CE78772-AD3C-41CC-9FEC-CE0D84825032Q36025675-CCC47AC6-9307-4133-AE9F-4EE5665EF482Q36155593-B80B55E6-8B45-488F-AA80-AB1E766157E9Q36339059-48A89407-8FBA-4D66-A5AF-B76537723CA1Q36514771-91DB1B87-548C-4025-990A-05BF214282B3Q36520832-C72E4672-2FD9-4F59-A355-CB0D87F95A95Q36555158-8D18C93D-A64A-4118-91BE-3B5EF573BD72Q36736366-6C4E3057-1920-4480-82CC-E36A0860F426Q36861306-9E5FFF27-CCAD-4723-BB86-3DF7E5F8F250Q36977847-F155CF42-7D1F-4E18-8DEA-0E6FE78DAA5EQ37316071-BBA36F44-4669-4A3D-9B7E-6961CACA060CQ37384857-15E090E8-3CEF-4B3A-9587-A46C8F0C0DDDQ37428262-FB554A6B-EB54-4507-8A38-50A7B59B0D64Q37460727-92D5570F-91DD-4A0F-B16F-9E652A4810BEQ37560770-A10A7ABA-BBC9-4304-AAFC-D9709AE00498Q37611796-D1F9EDE2-3F00-435A-B50F-1FA028AD8223Q37679220-09A41F28-B0CE-40BC-85A6-88F8955F057FQ37705702-A849023D-0AE7-4934-89BC-AE2243CD82E2Q37712799-4E395B26-F8DA-4CE5-9434-8190E4234F3BQ37991272-F1517982-FDC9-42E9-A1B8-3191A14BF440
P2860
A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
A genital tract peptide epitop ...... simplex virus type 2 challenge
@ast
A genital tract peptide epitop ...... simplex virus type 2 challenge
@en
type
label
A genital tract peptide epitop ...... simplex virus type 2 challenge
@ast
A genital tract peptide epitop ...... simplex virus type 2 challenge
@en
prefLabel
A genital tract peptide epitop ...... simplex virus type 2 challenge
@ast
A genital tract peptide epitop ...... simplex virus type 2 challenge
@en
P2093
P2860
P356
P1433
P1476
A genital tract peptide epitop ...... simplex virus type 2 challenge
@en
P2093
A A Chentoufi
A B Nesburn
D Carpenter
G Dasgupta
L BenMohamed
S L Wechsler
P2860
P2888
P304
P356
10.1038/MI.2008.81
P577
2008-12-24T00:00:00Z
P5875
P6179
1039113166